Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President & Representative Director: Masayuki Mitsuka) and Janssen Pharmaceutical K.K. (Hereafter “Janssen”; Headquarters: Chiyoda-ku, Tokyo; President: Chris Hourigan) have updated the strategic co-promotion agreement for STELARA® (ustekinumab), a monoclonal antibody that binds to the p40 subunit of human anti-interleukin (IL)-12 and IL-23 in Japan. Under the terms of the new agreement, effective June 27, 2018, domestic distribution of STELARA® will be transferred from Janssen to Mitsubishi Tanabe Pharma.

Mitsubishi Tanabe Pharma and Janssen will continue to jointly promote STELARA® to treat patients living with Crohn’s Disease in Japan. For the indication of psoriasis, promotion will be handled solely by Janssen.

Mitsubishi Tanabe Pharma and Janssen will also continue to co-promote SIMPONI®(golimumab) to treat patients living with moderate to severe rheumatoid arthritis or ulcerative colitis in Japan, under the terms of a strategic co-promotion agreement, which was updated in March 2017. Mitsubishi Tanabe Pharma continues to have sole distribution rights for SIMPONI® in Japan.

Janssen continues to hold the marketing authorization for both products in existing and new indications.

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
Media contacts: TEL:+81 6 6205 5119
Investor contacts: TEL:+81 6 6205 5110